Hematological Malignancies

Rituximab maintenance vs observation in relapsed FL (EORTC 20981): Overall survival

5 years

100

Rituximab maintenance 74.3%

80

60

Observation 64.7%

40

20

HR = 0.70 p = 0.07 Overall survival (%)

0

4

5

0

1

2

6

7

8

3

Time (years)

Number of patients at risk

167 167

155 161

139 150

128 141

104 124

67 86

28 44

13

9